Other Clinical Trial - Improving Cognition Via Exercise in Schizophrenia

Status Completed

Clinical Trial Summary

People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime. The goal of the proposed study is to examine the impact of remote exercise training on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.

Clinical Trial Description

The goal of the proposed study is to examine the impact of remote exercise training on cognitive functioning in people with schizophrenia. People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functional outcome and disability, thus representing an important public health concern and a target for interventions. At present, available treatments offer only minimal to limited benefits to ameliorate these deficits. Extensive animal and human research literatures converge in supporting the positive influence of aerobic exercise training on cognitive functioning. Preliminary data indicate that aerobic exercise training is effective in improving cognitive functioning in people with schizophrenia. However, previous studies employed small samples, focused on a single or limited range of cognitive domains, and/or collected insufficient information on daily functioning or putative biomarkers underlying cognitive change. Supported by supplement funding from NIMH, the goal of the proposed study is also to explore the impact of remote exercise training on suicide risk in individuals with schizophrenia. People with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime, and an estimated 5-10% actually being successful in completing suicide. This highly elevated risk represents a serious public health concern and an important target for interventions. However, available treatments offer only minimal to limited benefits to ameliorate this risk. Extensive animal and human research literatures converge in supporting the positive influence of AE training on a number of predictors of suicide risk including depressed mood, sleep difficulties, and poor cognition. Yet, at present there are no studies directly examining the impact of AE on suicide risk in this population. ;

Study Design

Related Conditions & MeSH terms

Schizophrenia
Schizophrenia and Related Disorders

Clinical Trial Details

NCT number	NCT03270098
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	N/A
Start date	April 26, 2018
Completion date	January 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05083377` - Clozapine Use Pattern in the Province of Seville
Recruiting	`NCT06313918` - Exercise Therapy in Mental Disorders-study	N/A
Recruiting	`NCT06134661` - Accelerated rTMS for Psychomotor Slowing	N/A
Completed	`NCT01433094` - Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia	N/A
Terminated	`NCT05526833` - An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study	N/A
Recruiting	`NCT05982158` - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices	N/A
Active, not recruiting	`NCT06175559` - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia	N/A
Active, not recruiting	`NCT05673941` - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia	N/A
Recruiting	`NCT02916810` - TMS for Symptom Reduction in Schizophrenia	N/A
Recruiting	`NCT05958875` - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.	Phase 4
Recruiting	`NCT03525054` - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting	`NCT05389345` - tDCS and Executive Function Training for Schizophrenia	N/A
Completed	`NCT05601050` - Linguistic Predictors of Outcomes in Psychosis
Completed	`NCT03075202` - Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
Completed	`NCT03921450` - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)	N/A
Completed	`NCT06231407` - Increasing Medication Check Participation Through Applying CT-r	N/A
Recruiting	`NCT04478838` - "Extended" (Alternate Day) Antipsychotic Dosing	Phase 4
Completed	`NCT04366401` - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders	N/A
Completed	`NCT04612777` - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses	N/A
Not yet recruiting	`NCT06191965` - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.